1887
Rapid communication Open Access
Like 0

Abstract

We evaluated SARS-CoV-2 RNA and neutralising antibodies in blood donors (BD) residing in the Lodi Red Zone, Italy. Of 390 BDs recruited after 20 February 2020 − when the first COVID-19 case in Lombardy was identified, 91 (23%) aged 19–70 years were antibody positive. Viral RNA was detected in an additional 17 (4.3%) BDs, yielding ca 28% (108/390) with evidence of virus exposure. Five stored samples collected as early as 12 February were seropositive.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.24.2001031
2020-06-18
2020-11-26
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2020.25.24.2001031
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/24/eurosurv-25-24-2.html?itemId=/content/10.2807/1560-7917.ES.2020.25.24.2001031&mimeType=html&fmt=ahah

References

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. , China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.  https://doi.org/10.1056/NEJMoa2001017  PMID: 31978945 
  2. World Health Organization (WHO). Novel coronavirus – China. Geneva: WHO; 12 Jan 2020. [Accessed 19 Jan 2020]. Available from: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
  3. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335.  https://doi.org/10.1001/jama.2020.4344  PMID: 32181795 
  4. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020.  https://doi.org/10.1002/jmv.25882  PMID: 32293713 
  5. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757-65.  https://doi.org/10.1172/JCI138745  PMID: 32254064 
  6. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490-6.  https://doi.org/10.1073/pnas.2004168117  PMID: 32253318 
  7. Zhao Q, He Y. Challenges of Convalescent Plasma Therapy on COVID-19. J Clin Virol. 2020;127:104358.  https://doi.org/10.1016/j.jcv.2020.104358  PMID: 32305026 
  8. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14):e149.  https://doi.org/10.3346/jkms.2020.35.e149  PMID: 32281317 
  9. Syal K. COVID-19: Herd immunity and convalescent plasma transfer therapy. J Med Virol. 2020.  https://doi.org/10.1002/jmv.25870  PMID: 32281679 
  10. Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020;vox.12926.  https://doi.org/10.1111/vox.12926  PMID: 32240545 
  11. Percivalle E, Cassaniti I, Sarasini A, Rovida F, Adzasehoun KMG, Colombini I, et al. West Nile or Usutu Virus? A Three-Year Follow-Up of Humoral and Cellular Response in a Group of Asymptomatic Blood Donors. Viruses. 2020;12(2):157.  https://doi.org/10.3390/v12020157  PMID: 32013152 
  12. Corman V, Bleicker T, Brünink S, Drosten C. Diagnostic detection of 2019-nCoV by real-time RT-PCR. Geneva: World Health Organization; 17 Jan 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf
  13. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.  https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045  PMID: 31992387 
/content/10.2807/1560-7917.ES.2020.25.24.2001031
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error